Pseudohyperaldosteronism: Pathogenetic mechanisms

Critical Reviews in Clinical Laboratory Sciences

Volumn 40, Issue 3, 2003, Pages 295-335

  Armanini, Decio ^a   Calò, Lorenzo ^a   Semplicini, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

11 hydroxysteroid dehydrogenase; Apparent Mineralocorticoid Excess Syndrome; Conn's syndrome; Cushing's syndrome; Desoxycorticosterone; Gene mutations; Licorice derivatives; Liddle's syndrome; Mineralocorticoid receptor; Sodium channels

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 18 HYDROXYDEOXYCORTICOSTERONE; ALDOSTERONE; ALDOSTERONE RECEPTOR; ANDROGEN; CARBENOXOLONE; CORTICOSTEROID; CORTISONE; DEOXYCORTICOSTERONE; ESTROGEN; FLUDROCORTISONE; GLYCYRRHETINIC ACID; GLYCYRRHIZA EXTRACT; HYDROCORTISONE; ISOFLUPREDONE; MINERALOCORTICOID; ORAL CONTRACEPTIVE AGENT; PROTEIN SUBUNIT; SODIUM CHANNEL;

ALDOSTERONE URINE LEVEL; BETA CHAIN; CARCINOGENESIS; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; CONTRACEPTION; CUSHING SYNDROME; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME MODIFICATION; EPITHELIUM CELL; ESSENTIAL HYPERTENSION; ESTROGEN ACTIVITY; ESTROGEN THERAPY; ESTROGEN URINE LEVEL; FAILURE TO THRIVE; GENE MUTATION; GENETIC DISORDER; GLYCYRRHIZA URALENSIS; HISTORY; HORMONAL CONTRACEPTION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERALDOSTERONISM; HYPOKALEMIA; IN VITRO STUDY; IN VIVO STUDY; LIDDLE SYNDROME; LOW BIRTH WEIGHT; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; POLYDIPSIA; POLYURIA; POTASSIUM URINE LEVEL; PREECLAMPSIA; PRIORITY JOURNAL; PROGESTERONE URINE LEVEL; REDUCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM URINE LEVEL; STEROIDOGENESIS; UPREGULATION;

CITRUS X PARADISI; GLYCYRRHIZA; GLYCYRRHIZA URALENSIS;

EID: 0038434121     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/713609355     Document Type: Review

References (177)

1. Kater CE, Biglieri EG, Brust, et al. Stimulation and suppression of the mineralocorticoid hormones in normal subjects and adrencocorticortical disorders. Endocr Rev 1989; 10: 149-164.
2. Quinn SJ, Williams GH. Regulation of aldosterone secretion. Annu Rev Physiol 1988: 50: 409-426.
3. Williams GH, Dluhy RG. Control of aldosterone secretion. In: Genest J, Küchel O, Hamet P, eds. Hypertension: Physiopathology and Treatment. 2nd ed. Pp 320-337. New York: McGraw-Hill, 1983.
4. McKenna TJ, Island DP, Nicholson WE, et al. The effects of potassium on early and late steps in aldosterone biosynthesis in cells of the zona glomerulosa. Endocrinology 1978: 103: 1411-1416.
5. Kramer RE, Gallant S, Brownie AC. Actions of angiotensin II on aldosterone biosynthesis in the rat adrenal cortex. J Biol Chem 1980; 255: 3442-3447.
6. Himathongkam T, Dluhy RG, Williams GH. Potassium-aldosterone-renin interrelationships. J Clin Endocrinol Metab 1975; 41: 153-159.
7. Knox FG, Burnett JC Jr, Kohan DE, et al. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Int 1980; 65: 765-772.
8. Miyamori I, Ikeda M, Matubara T, et al. Human natriuretic polypeptide during escape from mineralocorticoid excess in man. Clin Sci 1987; 73: 431-436.
9. Armanini D, Witzgall H, Wehling M, et al. Aldosterone receptors in different types of primary hyperaldosteronism. J Clin Endocrinol Metab 1987; 65: 101-104.
10. Irony I, Biglieri EG. The Sindrome of hyperdeoxycorticosteronism. In: Biglieri EG, Melby JC, eds. Endocrine Hypertension. Pp 175-181. New York: Raven Press, 1990.
11. Kono T, Miyake T. The volume of distribution, metabolic clearance rate and mean plasma concentration of aldosterone, cortisol and corticosterone in various clinical conditions. Proc Second Internat Congr Endocrinol. Excerpta Med Congr Series. 1965; 83: 246-257.
12. Sasano H, Fukushima K, Sasaki I, et al. Immunolocalization of mineralocorticoid receptor in human kidney, pancreas, salivary, mammary and sweat glands: a light and electron microscopic immunohistochemical study. J Endocrinol 1992; 132: 305-310.
13. Fukushima K, Sasano H, Nagura H. Immunohistochemical localization of mineralocorticoid receptor in human gut. Tohoku J Exp Med 1991; 165: 155-163.
14. Pressley L, Funder IW. Glucocorticoid and mineralocorticoid receptors in gut mucosa. Endocrinology 1975; 97: 588-596.
15. Gesing A, Bilang BA, Droste SK, et al. Psychological stress increases hippocampal mineralocorticoid receptor levels: involment of corticotropin-releasing hormone. J Neurosci 2001; 21: 4822-4829.
16. Rahmouni K, Sibug RM, De Kloet ER, et al. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension. Eur J Pharmacol 2002; 436: 207-216.
17. Le Menuet D, Isnard R, Bichara M, et al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 2001; 276: 38911-20.
18. Armanini D, Strasser T, Weber PC. Characterization of aldosterone receptors in human mononuclear leukocytes. Am J Physiol 1985; 11, E388-390.
19. Suzuki T, Sasano H, Suzuki S, et al. 11 beta-hydroxysteroid dehydrogenase type 2 in human lung: possible regulator of mineralocorticoid action. J Clin Endocrinol Metab 1998; 83: 4022-4025.
20. Stokes J, Noble J, Brett L, et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenase in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000; 41: 1629-1638.
21. Mirshahi M, Mirshahi A, Sedighian R, et al. Immunochemical demonstration of the mineralocorticoid receptor in ocular tissue. Neuroendocrinology 1997; 65: 70-78.
22. Funder JW. Mineralocorticoid receptors and glucocorticoid receptors. Clin Endocrinol (Oxford) 1996; 45: 651-656.
23. Schild L, Kellenberger S. Structure function relationships of ENaC and its role in sodium handling. Adv Exp Med Biol 2001; 502: 305-314.
24. Eaton DC, Malik B, Saxena NC, et al. Mechanisms of aldosterone's action on epithelial Na + transport. J Membr Biol. 2001; 184: 313-319.
25. Rossier C, Pradervand S, Schild L, Hummler E. Epithelial sodium channel and the control of sodium EnaC. Annu Rev Physiol 2002; 64: 877-897.
26. Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epthelia sodium channel cause salt wasting with hyperkaliemic acidosis, pseudohyperaldosteronism type I. Nat Genet 1996; 12: 248-253.
27. Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000; 57: 1364-1368.
28. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983; 80: 6056-6060.
29. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988: 242: 583-585.
30. Stewart PM, Wallace AM, Valentino R, et al. Mineralocorticoid activity of licorice: 11β hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 1: 82-86.
31. Gomez Sanchez CE, Gomez-Sanchez EP, Yamakita N. Endocrine causes of hypertension Semin Nephrol 1995; 15:106-115
32. Edwards CRW, Stewart PM, Burt D, et al. Localization of 11βHSD-tissue specificity protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-989.
33. Palermo M, Delitala G, Mantero F, et al. Congenital deficiency of 11β-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary-free cortisol and cortisone. J Endocrinol Invest 2001, 24: 17-23.
34. Agarwal AK. Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J Biol Chem 1989; 264: 19939-18943.
35. Albiston AL, Obeyesekere VR, Smith RE, et al. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: R11-R17.
36. Conn, JW, Knopf RF, Nesbit RM. Primary aldosteronism: present evaluation of its clinical characteristics and of the results of surgery. In: EE Baulieu and P Robel, eds. Aldosterone. Pp 327-338. Oxford: Blackwell Scientific Publications 1964.
37. Gross EG, Dexter JD, Roth HG. Hypokalaemic myopathy with myoglobinuria associated with licorice ingestion. N Engl J Med 1966; 274: 602-604.
38. Theophrastus: Inquiry into Plants and Minor Works on Odours and Weather Signs (transl. by Hort A), IX, 13. Harvard University Press, London, 1961.
39. Plinius: C. Plinii Secundi Naturalis historiae libri XXXVII, XI, 119; XXV, 43. II: Teubneri, Lipsiae, 1875; IV.
40. Baumann EJ, Kurland S. Changes of the inorganic constituents of blood in suprarenalectomized cats and rabbits. J Biol Chem 1927; 71: 281.
41. Kendall EC. Adrenal cortex extracts. JAMA 1932; 105: 1486.
42. Wintersteiner O, Pfiffner JJ. Chemical studies on the adrenal cortex III isolation of two new physiologically inactive compounds. J Biol Chem 1936; 116: 291-295.
43. Rubin MI, Krick ET. Effect of adrenalectomy on salt metabolism in rat. Proc Soc Exp Biol 1933; 31: 228-33.
44. Reichestein T, von Euw J. Uber Bestandteile der Nebenniererinde. XX. Isolierung der Substanze Q (Desoxycorticosterone) und R sovie weitere Stoffe. Helv Chim Acta 1938; 21: 1197.
45. Wintersteiner O, Vars HM, Pfiffner JJ. Chemical investigation of the cortical hormone of the adrenal gland. J Biol Chem 1934; 105: 100-102.
46. Hartman FA, Spoor HJ, Lewis LA. Sodium factor and the adrenal. Science 1939; 89: 204-208.
47. Kendall EC The function of the adrenal cortex. Proc Staff Meet Mayo Clin 1940; 15: 297-241.
48. Grollman A. The comparative activity of desoxycorticosterone and other crystalline derivatives and of purified extracts of the adrenal cortex. J Pharmac Exp Therap 1939; 67: 257-262.
49. Hartman FA. Functions of the adrenal cortex. Endocrinology 1942; 30: 861-865.
50. Revers FE. Heedt succus liquiritiae een gegenzde werking of de maagweer? Nedl Tijdschr Geneesk 1946; 90: 135-137.
51. Revers FE. Licorice juice in the therapy of ventricular and duodenal ulcers. Ned Tijdschr Geneesk 1948; 92: 2968-2971.
52. Molhuysen JA, Gerbandy J, de Vries LA, et al. A licorice extract with desoxycorticosterone like effect. Lancet 1950; 2: 381-386.
53. Groen J, Pelser H, Willebrands AF, et al. Extract of licorice for treatment of Addison's disease. N Engl J Med 1951; 244: 471-475.
54. Strong JA. Serum potassium deficiency during treatment with PAS and liquorice extract. Br Med J 1951; 4378: 998-1002.
55. Selye H. Physiology and Pathology of Exposure to Stress. Montreal: Acta Inc Med Publisher, 1950.
56. Earle DP, Sherry S, Eichna LW, et al. Low potassium syndrome due to defective renal tubular mechanism for handling potassium. Am J Med 1951; 11: 283-301.
57. Amelung D. Conversion of cortisone to compound F. J Clin Endocrinol Metab 1953; 13: 1125-1128.
58. Peterson RE. Metabolism of adrenal cortical steroids. In: Christy ND, ed. The Human Adrenal Cortex. Pp 87-98. New York: Harper and Row, 1971.
59. Simpson SA, Tait JF. Physicochemical methods of detection of a previously unidentified adrenal hormone. Mem Soc Endocr 1953; 2: 91-94.
60. Simpson SA, Tait JF. A quantitative method for the bioassay of the effect of the adrenal cortical steroids on mineral metabolism. Endocrinology 1952; 5: 150-161.
61. Louis LH, Conn JW. Preparation of glycyrrhizinic acid, the electrolyte-active principle of licorice: its effects upon metabolism and upon pituitary-adrenal function in man. J Lab Clin Med 1956; 47: 20-28.
62. Gross F. Renin und hypertensin physiologische oder pathologische Wirkstoffe? Klin Wschr 1958; 36: 693-706.
63. Jenny M, Muller AF, Fabre J, et al. Hypokaliemie calose par ingestion abusive d' extrait de reglisse et d'eau bicarbonatee. Pseudosyndrome de Conn. Schweiz med Wschr 1961; 91: 869-875.
64. Drosdowski M, Robel P, Sebaoun J. Syndrome de depletion potassique simulant une maladie de Conn, provoquè par la glycyrrhizin. Presse Med 1961; 69: 294-295.
65. Salassa RM, Mattox VR, Roseviar JW. Inhibition of the mineralocorticoid activity of licorice by spironolactone. J Clin Endocrinol 1962; 22: 1156-1159.
66. Sturcz J, Solyom J, Kotra ZS, et al. Role of the renin-angiotensin system on the regulation of aldosterone excretion. Excerpta Med Int Congr Series 1963; 67: 378-380.
67. Liddle JW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion In: Baulieu EE, Robel P, eds. Aldosterone. Pp 353-368. Oxford: Blackwell Scientific Publications, 1964.
68. Conn JW, Rovner DR, Cohen EL. Licorice-induced pseudoaldosteronism. JAMA 205: 80-84,1968.
69. Feldman D, Funder JW, Edelman IS. Subcellular mechanisms in the action of adrenal steroids. Am J Med 1972; 53: 545-60.
70. Werder EA, Zachmann M, Wollmin J, et al. Unusual steroids excretion in a child with low renin hypertension. Res Steroids 1974; 6: 385-392.
71. Ulmann A, Menard J, Corvol P. Binding of glycyrrhetinic acid to kidney mineralocorticooid and gluicocorticoid receptors. Endocrinology 1975; 97: 46-50.
72. New MI, Levine L, Biglieri EG, et al. Evidence of an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977, 44: 929-934.
73. Epstein MT, Espiner EA, Donald RA, Hughes H. Effect of eating liquorice on the renin angiotensin aldosterone axis in the normal subjects. Br Med J 1977; I: 488-490.
74. Epstein MT, Espiner EA, Donald RA, et al. Licorice raises urinary cortisol in man. J Clin Endocrinol Metab 1978; 47: 397-400.
75. Ulick S, Levine L, Gunczler P, et al. A syndrome of apparent mineralocorticoid excess associated with a defect in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49, 757-764
76. Tamura Y, Nishikawa T, Yamada K, et al. Effects of glycyrrhetinic acid and its derivatives on 4-α and 5 β reductase in rat liver. Azneimittelforschung 1979; 29: 47-49.
77. Armanini D, Karbowiak I, Krozowski Z, et al. The mechanism of mineralocorticoid action of carbenoxolone. Endocrinology 1982; 111: 1683-1686.
78. Armanini D, Karbowiak J, Funder JW. Affinity of licorice derivatives for mineralocorticoid and glucocorticoid receptors. Clin Endocrinol (Oxford) 1983; 19: 606-609.
79. Hoefnagels WHL, Kloppenborg WC. Antimineralocorticoid effects of dexamethasone in subjects treated with glycyrrhizic acid. J Hypertension 1983; 1: 313-315.
80. Armanini D, Zennaro MC, Martella L, et al. Regulation of aldosterone receptors in hypertension. Steroids 1993; 58: 611-613.
81. Wehling M, Armanini D, Strasser T, et al. Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. Am J Physiol 1987; 252: E505-508.
82. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-275.
83. Armanini D, Wehling M, Weber PC: Mineralocorticoid effector mechanism of licorice derivatives in human mononuclear leukocytes. J Endocrinol Invest 1989; 12: 303-306.
84. Armanini D, Scali M, Zennaro MC, et al. The pathogenesis of pseudohyperaldosteronism from carbonexolone. J Endocrinol Invest 1989; 12: 337-314.
85. Dorfman RI, Potts AM, Feil ML. Studies of the bioassay of hormones: the use of radiosodium for the detection of small quantities of desoxycorticosterone. Endocrinology 1947; 41: 464-469.
86. Mattox VR, Mason HL, Albert A. Isolation of a sodium retaining substance from beef adrenal extracts. Proc Staff Meet Mayo Clinic 1953; 28, 569-576.
87. Bartter FC. The role of aldosterone in normal homeostasis and in certain diseases Metabolism 1956; 3: 369-379.
88. Kliman B, Peterson RE. Isotope derivative assay of aldosterone in biological extracts. Fed Proc 1958; 17: 255-262.
89. Ulick S, Laragh JH, Lieberman S, et al. The isolation of a urinary metabolite of aldosterone and its use to measure the rate of secretion of aldosterone by the adrenal cortex of man Trans. Ass Am Physns 1958; 71: 225-234.
90. Genest J, Boucher R, De Champlain J, et al. Studies on the renin angiotensin system in hypertensive patients. CMAJ 1964; 90: 263-271.
91. Morris DJ, Berek JS, Davis RP. Physiological response to aldosterone in adrenalectomised and intact rats and its sex dependence. Endocrinology 1973; 92: 989-992.
92. Edmonds CJ, Marriot J. The effect of aldosterone and adrenalectomy on the electrical potential difference of rat colon and on the transport of sodium, potassium, chloride and bicarbonate. J Endocrinol 1967; 39: 517-531.
93. Skrabal F, Aubock J, Edwards CR, et al. Subtraction potential difference: in vivo assay for mineralocorticooid activity. Lancet 1978; i: 298-302.
94. Mayes D, Furuyama S, Kem DC, et al. A radioimmunoassay for aldosterone. J Clin Endocrinol Metab 1970; 30: 682-688.
95. Stockigt JR, Collins RD, Biglieri EG. Determination of plasma renin concentration by angiotensin I immunoassay. Diagnostic import of precise measurement of subnormal renin in hyperaldosteronism. Circ Res 1971; 28: 175-191.
96. Lan CN, Matulich DT, Stockigt JR, et al. Role of steroids in various stated of mineralocorticoid-excess: analysis by mineralocorticoid receptor assay. In: Giovannelli G, ed. Hypertension in Children and Adolescents. Pp 165-175. New York: Raven Press, 1981.
97. Armanini D, Lewicka S, Pratesi C, et al. Further studies on the mineralocorticoid action of licorice in humans. J Endocrinol Invest 1996; 19: 624-629.
98. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119-123.
99. Heilmann P, Buchlein E, Wacker J, et al. Alteration of the activity of the 11β-hydroxysteroid dehydrogenase in pregnancy: relevance for the development of pregnancy-induced hypertension? J Clin Endocrinol Metab 2001; 86: 5222-5226.
100. Ferrari P, Krowowski Z. Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int 2000; 57: 1374-1381.
101. Mune T, Roberson FM, Nikkila H et al. Human hypertension caused by mutation in the kidney isoenzyme of 11 β-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394-399.
102. Mach RS Fabvre J, Duckert A, Borth R. Action clinique et metabolique de l'aldosterone (electrocortine). Schweiz Med Wschr 1959; 51: 229-237.
103. Coghlan JP, Denton DA, Goding JR Wright RD. The control of aldosterone secretion. Postgrad Med J 1960; 36: 76-82.
104. Collins KJ. The action of exogenous aldosterone on the secretion and composition of drug-induced sweat. Clin Sci 1966; 30: 207-211.
105. Charron RC, Leme CE, Wilson DR, et al. The effect of adrenal steroids on stool composition, as revealed by in vivo dialysis of feces. Clin Sci 1969; 37: 151-159.
106. Conn JW, Louis HL, Johnston MW, et al. The electrolyte content of thermal sweat as an index of adrenal cortical function. J Clin Invest 1948; 27: 529-533.
107. Armanini D, Zennaro MC, Martella L, et al. Mineralocorticoid effector mechanism in preeclampsia. J Clin Endocrinol Metab 1992; 74: 946-949.
108. Warnock DG. Genetic forms of human hypertension. Curr Opin Nephrol Hypertens 2001; 10: 493-9.
109. Hakan R, Toka HR, Luft F. Monogenic forms of human hypertension. Sem Nephrol 2002; 22: 81-88.
110. Persu A, Barbry P, Bassilana F et al. Genetic analysis of the beta subunit of the epithelial sodium channel in essential hypertension. Hypertension 1998; 32: 129-137.
111. Melander O, Orho M, Fagerudd J, et al. Mutations and variants of the epithelial sodium channel gene in Liddle's syndrome and primary hypertension. Hypertension 1998; 31: 1118-1124.
112. Latif SA, Conca TJ, Morris DJ. The effect of the licorice derivative glycyrrhetinic acid on hepatic 3α and 3β hydroxysteroid dehydrogenase and 5α and 5β reductase pathways metabolism of aldosterone in male rats. Steroids 1990; 55: 52-60.
113. Scali M, Pratesi C, Zennaro MC, et al. Pseudohyperaldosteronism from licorice-containing laxatives. J Endocrinol Invest 1990; 13: 847-848.
114. Mitchell W, Strong JA, Taylor NRW, et al. Effects of liquorice and its derivates on salt and water metabolism. Lancet 1953; i: 663-666.
115. Blachley JD, Knochel JP. Tobacco chewer's hypokalemia: licorice revisited. N Engl J Med 1980; 302: 784-785.
116. Ferrari P, Trost BN. A case from practice. Liquorice induced pseudohyperaldosteronism in a previously alcoholic woman caused by the drinking of an alcohol free pastis substitute beverage. Schweiz Rundsch Med Prax 1990; 79: 377-378.
117. Farese RV Jr, Biglieri EG, Shackleton CH, et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1233-1237.
118. Helmann P, Heide J, Hundertmark S, et al. Administration of acid: significant correlation between serum levels and the cortisol/cortisone ratio in serum and urine. Exp Clin Endocinol Diabetes 1999; 107: 370-378.
119. Ferrari P, Sansonnens A, Dick B, et al. In vivo 11βHSD2 activity variability, salt sensitivity and effect of licorice. Hypertension 2001; 38:1330-1336.
120. Pinder RM, Brogden RN, Stawyer PR, et al. Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs 1976; 11: 245-287.
121. Baron JH. Side-effects of carbenoxolone. Acta Gastroenterol Belg 1983; 46: 463-471.
122. Porter GA. Synergistic effect of carbenoxolone sodium on aldosterone-enhanced sodium transport in toad skin. In: Baron GHO, Sulivan FM, eds. Carbenoxolone Sodium. pp 34-47. London: Butterfield, 1970.
123. Morris DJ, Sounes JW. The 11βOHSD inhibitor carbenoxolone enhanced Na retention by aldosterone and 11 desoxycorticosterone. Am J Physiol 1990; 258: F756-759.
124. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol 1992; 263: E1125-1130.
125. Song DJ, Lorenzo B, Reidenberg MM. Inhibition of 11βhydroxysteroid dehydrogenase by gossypol and bioflavanoids. J Lab Clin Med 1992; 120: 792-797.
126. Lee JS, Lorenzo BJ, Koufis T, et al. Grapefruit juice and its flavanoids inhibit 11β hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996; 59: 62-71.
127. Irony I, Biglieri EG, Perloff D, et al. Pathophysiology of desoxycorticosterone secreting adrenal tumors. Clin Endocrinol Metab 1987; 65: 836-840.
128. Kondo K, Saruta T, Saito I. Benign desoxycorticosterone producing adrenal tumor. JAMA 1976; 236: 1042-1044.
129. Doerr HG, Sippel WG, Drop SL Evidence of 11 β-hydroxylase deficiency in children adrenocortical tumors. The plasma corticosterone/11deoxycorticosterone ratio as a possible marker of malignancy. Cancer 1987; 60: 1625-1629.
130. Sheppard TH, Clausen SW. Case of adrenogenital syndrome with hypertension-treated with cortisone. Pediatrics 1951; 8: 805-808.
131. White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (arg448→his) associated with steroid 11 βhydroxylase deficiency in Jews of Morrocan origin. J Clin Invest 1991; 87: 1664-1667.
132. Lipsett M, Wilson H. Adrenocortical cancer: steroid synthesis and metabolism evaluated by urinary metabolites. J Clin Endocrinol Metab 1962; 22; 906-915.
133. Mantero F, Opocher G, Armanini D, et al. 11β hydroxylase deficiency. J Endocrinol Invest 1995; 18: 545-549.
134. Mantero F, Busnardo B, Riondel Aveyrat R, et al. Arterial hypertension, hypokalemia alkalosis and male pseudohermaphroditism caused by 17alpha hydroxylase deficiency. Schweiz Med Wochenschr 1971; 101: 38-43.
135. Biglieri EG. 17α-hydroxylase deficiency. J Endocrinol Invest 1995; 18: 540-544.
136. Powell-Jackson JD, Calin A, Freser A. Excess deoxycorticosterone secretion from adrenocortical carcinoma. Br Med J 1974; 2: 32-33.
137. Biglieri EG, Herron MA, Brust N. 17α hydroxylase deficiency in man. J Clin Invest 1954; 45: 1946-1954.
138. Mills IH, Wilson RJ, Tait AD, et al. Steroid metabolic studies in a patient with 17α-hydroxylase deficiency syndrome. J Endocrinol 1967: 38: 19-24.
139. Melby JC, Dahle SL, Grekin R, et al. 18-hydroxydeoxycorticosterone secretion in experimental human hypertension. Prog Horm Res 1972; 28: 287-351.
140. Irony I, Biglieri EG, Kater CE. The adrenocortical hormones in hypertensive disorders. In: Laragh JH, Brenner BM, Kaplan NM, eds. Endocrine Mechanism in Hypertension. Pp 1-18. New York: Raven Press, 1989.
141. Vita G, Bartolone S, Santoro M, et al. Hypokalemic myopathy in pseudohyperaldosteronism induced by fluoroprednisolone-containing nasal spray. Clin Neuropathol 1987; 6: 80-85.
142. Marin F, Gonzales QA, Moya M, et al. Pseudohyperaldosteronism due to application of an anti-hemorroid cream. Nephron 1989; 52: 281-282.
143. Ambruster H, Vetter W, Reigh G, et al. Severe arterial hypertension caused by chronical abuse of a topical mineralocorticoid. Int J Pharmacol 1975; 12: 170-173.
144. Mantero F, Armanini D, Opocher G, et al. Mineralocorticoid hypertension due to a nasal spray containing 9α fluoroprednisolone. Am J Med 1981; 71: 352-357.
145. Mijares M. Hypocalemic rhabdomyolysis secondary to pseudohyperaldosteronism due to the use of a lotion containing 9α fluoroprednisolone. Nephron 1986; 43: 232-233.
146. Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979; 301:68-73.
147. Page B, Zahir A, Grunfield JP. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60-65.
148. Whithworth JA. Mechanisms of glucocorticoid-induced hypertension in humans. Hypertension 1992; 19: 567-574
149. Miyamori I. Mechanism of hypertension in Cushing's syndrome: possible role of 11β hydroxysteroid-dehydrogenase. Intern Med 2002; 41: 249-250.
150. Stewart PM. Cortisol as a mineralocorticoid in human disease. J Ster Biochem Molec Biol 1999; 69: 403-408.
151. Melander O, Orho-Melander M, Bengtsson K, et al. Association between a variant in the 11β hydroxysteroid dehydrogenase type 2 gene and primary hypertension. J Hum Hypertens 2000; 14: 819-823.
152. Mune T, Rogerson FM, Nikkila H et al. Human hypertension caused by mutation in the kidney isoenzyme of 11 β -hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394-399.
153. Odermatt A, Dick B, Arnold P. A mutation in the cofactor binding domain of 11β-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension J Clin Endocrinol Metab 2001; 86: 1247-1252.
154. Palermo M, Cossu M, Shackleton CHL. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 1998; 339: 1787-1788.
155. Sandeep TC, Walker BR. Pathophysiology of modulation of local glucocorticoid levels by 11β-hydroxysteroid dehydrogenase. Trends Endocrinol Metab 2001; 12: 448-453.
156. Kaplan NM. Hypertension induced by pregnancy, oral contraceptives and postmenopausal replacement therapy. Cardiol Clin 1988; 6: 475-482.
157. Kem DC. Sex steroids. In: Izzo JL, Black HR, eds. Hypertension. Pp 21-22. Dallas: Primer American Heart Association, 1993.
158. Saruta T, Ozawa Y, Asano S. The mechansism of estrogen hypertension. Jpn Circ J 1972; 36: 611-616.
159. Warnock DG. Low renin hypertension in the next millennium. Semin Nephrol 2000; 40: 6-21.
160. Rossi E, Regolisti G, Perazzoli F, et al. 344C/T polymorphism of CYP11B2 gene in Italian patients with low-renin hypertension. Am J Hypertens 2001; 14: 934-1941.
161. Fisher ND, Hurwitz S, Ferri C et al. Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension 1999; 34: 388-394.
162. Warnock DG. Low-renin and non-modulating essential hypertension. Hypertension 1999; 34: 395-397
163. Iki K, Miyamori I, Hatakeyama H, et al. The activities of 5β-reductase and 11-β hydroxysteroid dehydrogenase in hypertension. Steroids 1994; 59: 656-660.
164. Soro A, Ingram MC, Tonolo MG, et al. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5α-reductase in patients with untreated essential hypertension. Hypertension 1995; 25: 67-70.
165. Ambrosius WT, Bloem LJ, Zhou L, et al. Genetic variants in the epithelia sodium channel in relation to aldosterone and potassium excretion and of hypertension. Hypertension 1999; 34: 631-637.
166. Su YR, Rutkowski MP, Klanke CA et al. A novel variant of the beta subunit of the amiloride-sensitive sodium channel in African-Americans. J Am Soc Nephrol 1996; 7: 2543-49.
167. Baker EH, Dong YB, Sagnella GA, et al. Association of hypertension with T594M mutation in the beta subunit of epithelial sodium channels in black people resident in London. Lancet 1998; 51:1388-92.
168. Snyder PM. The epithelial sodium channel: cell surface insertion and retrieval in sodium homeostasis and hypertension. Endocr Rev 2002; 23: 258-275.
169. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265.
170. Lovati E, Ferrari P, Dick B, et al. Molecular basis of human salt sensitivity: the role of the β-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 2000; 85: 4921-23.
171. Manunta P, Cusi D, Barlassina C, et al. Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int. 1998; 53: 1471-8.
172. Manunta P, Burnier M, D'Amico M, et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33: 694-7.
173. Grant FD, Romero JR, Jeunemaitre X, et al. Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism. Hypertension 2002: 39:191-96.
174. Warnock DG. Liddle's syndrome: genetics and mechanisms of sodium channel defects. Contrib Nephrol 2001; 136: 1-10.
175. Morris DJ, Semafuko WEB, Latif SA, et al. Detection of glycyrrhetinic like factors in human urine. Hypertension 1992; 20: 356-360.
176. Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle's syndrome revisited - a disorder of sodium reabsorbtion in the distal tubule. N Engl J Med 1994: 330:178-181.
177. Lifton RP, Gharavi AG, Geller DS Molecular mechanism of human hypertension. Cell 2001; 104: 546-556.